* Pulmatrix Inc PULM.OQ PULM.O is expected to show a
rise in
quarterly revenue when it reports results on August 7
(estimated).
* The Lexington Massachusetts-based company is expected to
report
a 13.7% increase in revenue to $1.514 million from $1.33
million a year ago, according to the estimate from one analyst,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Pulmatrix Inc is
for a
loss of $1.23 per share.
* The one available analyst rating on the shares is "buy".
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "Buy".
* Wall Street's median 12-month price target for Pulmatrix
Inc is
$10, above its last closing price of $2.60.
This summary was machine generated August 4 at 18:36 GMT. All
figures in US dollars unless otherwise stated